课题基金 / 基金详情

项目摘要

项目成果

Jane Azizkhan-Clifford的其他基金

相似基金

相关文献

中文摘要
翻译
合理设计肿瘤化疗药物治疗方案 由于这组有毒药物具有广泛的 对正常细胞和转化细胞的影响范围。尽管 其中许多药物的特定生化作用机制是 据了解,它们对细胞过程的更广泛影响尚不清楚。 抗代谢物质的作用,它抑制特定的酶所需的 DNA或RNA的合成,可以通过增加 以酶为目标。我们使用二氢叶酸还原酶(DHFR)基因作为 演示甲氨蝶呤(MTX)处理细胞的模型系统 与其他抗代谢药物一起刺激dhfr转录 转染法(Eastman等人,Proc.娜塔莉。阿卡德。科学,美国,在 按下)。我们计划通过检查以下比率来扩展这些研究 内源基因转录对抗代谢药物的反应。至 进一步探讨应对措施,我们将确定效果是否 DFW启动子是独有的,我们将研究其他药物(如 氟代脱氧尿嘧啶核苷、羟基脲和2‘-脱氧辅酶A霉素)对DHFR和 它们各自的靶基因(胸苷合成酶、核糖核苷酸 还原酶和腺苷脱氨酶) 瞬时转染实验中启动子驱动的表达。这个 刺激转录与已知致病因素之间的关系 耐药性,基因扩增,也将被检测。我们建议 确定MTX通过以下途径刺激DHFR转录的机制 研究相关转录因子及其与细胞的相互作用 Dhfr启动子和细胞转录机制。然后我们就会 将我们的发现扩展到其他抗代谢物质及其靶基因。我们的 初步工作表明,用顺铂对细胞进行预处理可以防止 甲氨蝶呤对DHFR启动子的刺激作用。在此基础上 初步数据,我们建议检验几个关于 顺铂抑制转录增强的作用机制 由甲氨蝶呤引起。拟议的研究计划将增进我们的理解 耐药和交叉耐药,从而将导致 开发更有效的治疗癌症的方案 这些特工。
英文摘要
Rational design of cancer treatment protocols using chemotherapeutic agents has been hampered by the fact that this group of toxic drugs has a wide range of effects on both normal and transformed cells. Although the specific biochemical mechanisms of action of many of these drugs are understood, their broader effects on cellular processes remain unclear. The action of antimetabolites, which inhibit specific enzymes required for DNA or RNA synthesis, can be abrogated by increased production of the target enzymes. We have used the dihydrofolate reductase (DHFR) gene as a model system to demonstrate that treatment of cells with methotrexate (MTX) and with other antimetabolites stimulates DHFR transcription in a transient transfection assay (Eastman, et al., Proc. Natl. Acad. Sci., USA, In Press). We plan to extend these studies by examining rates of transcription of endogenous genes in response to antimetabolites. To further explore the response, we will determine whether the effect is unique to the DFW promoter, we will study the effects of other drugs (e.g. fluorodeoxyuridine, hydroxyurea, and 2'deoxycoformycin) on both DHFR and their respective target genes (thymidylate synthetase, ribonucleotide reductase, and adenosine deaminase) by nuclear run-on assays and by promoter driven expression in transient transfection assays. The relationship between stimulated transcription and a well-known cause of drug resistance, gene amplification, will also be examined. We propose to determine the mechanism whereby MTX stimulates DHFR transcription by studying relevant transcription factors and their interactions with the DHFR promoter and with the cellular transcription machinery. We would then extend our findings to other antimetabolites and their target genes. Our preliminary work shows that pre-treatment of cells with cisplatin prevents the stimulatory effect of MTX on the DHFR promoter. On the basis of these preliminary data, we propose to test several hypotheses concerning the mechanism of cisplatin action that may abrogate the increased transcription caused by MTX. The proposed research plan will enhance our understanding of drug resistance and cross-resistance, and will thereby lead to the development of more effective protocols for the treatment of cancers with these agents.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
E2F/Spl Synergy in Cell Cycle Regulated Transcription
  • 批准号:
    6344389
  • 项目类别:
  • 资助金额:
    $27.18万
  • 财政年份:
    2000
  • 负责人:
    Jane Azizkhan-Clifford
  • 依托单位:
E2F/Spl Synergy in Cell Cycle Regulated Transcription
  • 批准号:
    6788743
  • 项目类别:
  • 资助金额:
    $27.18万
  • 财政年份:
    2000
  • 负责人:
    Jane Azizkhan-Clifford
  • 依托单位:
E2F/Spl Synergy in Cell Cycle Regulated Transcription
  • 批准号:
    6522687
  • 项目类别:
  • 资助金额:
    $27.18万
  • 财政年份:
    2000
  • 负责人:
    Jane Azizkhan-Clifford
  • 依托单位:
E2F/Spl Synergy in Cell Cycle Regulated Transcription
  • 批准号:
    6378229
  • 项目类别:
  • 资助金额:
    $27.36万
  • 财政年份:
    2000
  • 负责人:
    Jane Azizkhan-Clifford
  • 依托单位:
海外基金